MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease (NCT05194163) | Clinical Trial Compass
UnknownPhase 2
MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
United States24 participantsStarted 2022-05-01
Plain-language summary
This study is a phase 2a randomized double-blind, placebo-controlled, study, in mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK kinase inhibitor. The primary goals of this study are to investigate the safety and tolerability, and drug movements in the body. The secondary goals of the study are to investigate the effects of the drug on cognitive performance, activities of daily living, and behavior, and the biological effects of the drug on blood biomarkers.
Who can participate
Age range
50 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Signed informed consent from subject (or legally authorized representative, LAR) and study partner.
. Male or female, age 50 to 90 inclusive.
. Have a study partner who is able to accompany the subject, has frequent contact with subject.
. Meet criteria for Alzheimer's Disease by NIAA-AA criteria.
. Must speak English fluently.
. Must have education of at least 8 years.
. Must have adequate hearing and visual abilities.
. MMSE score of 14 to 28.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Presence of clinically significant disorders of the central nervous system other than Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus, epilepsy, demyelinating disease, brain tumors, or psychiatric disorders (such as schizophrenia, or severe affective disorders).
. Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical disease.
. Abnormal liver function tests (ALT or AST) or creatine kinase (CK) upon repeat testing.
. Chronic hepatitis B or C infection, indicated by positive HBSAg, or HCV-Ab with HCV RNA presence.
. Known history of human immunodeficiency virus (HIV) infection.
. Known immune disorder that has a history of requiring treatment with immunosuppressive drugs within the past 1 year.
. Have a drug or alcohol abuse within 12 months prior to screening.
. Clinically significant laboratory abnormalities at screening.